<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635360</url>
  </required_header>
  <id_info>
    <org_study_id>18472</org_study_id>
    <secondary_id>UVA-LACC-PD201</secondary_id>
    <nct_id>NCT02635360</nct_id>
  </id_info>
  <brief_title>Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linda R Duska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in
      combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced
      cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will
      be administered after or during chemoradiation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in immunologic markers following combination of study drug with chemoradiation</measure>
    <time_frame>At 6 weeks of chemoradiation and 12 weeks post-chemoradiation</time_frame>
    <description>Expression of immune markers measured at pre and post administration of study drug with chemoradiation will be compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities</measure>
    <time_frame>From start of treatment until 12 weeks post-chemoradiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic Response Rate on PET/CT imaging</measure>
    <time_frame>12 weeks after chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of distant metastases</measure>
    <time_frame>From start of treatment until up to 5 years following end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From start of treatment until up to 5 years following end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From start of treatment until up to 5 years following end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Following chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent to chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.</description>
    <arm_group_label>Following chemoradiation</arm_group_label>
    <arm_group_label>Concurrent to chemoradiation</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>Radiation is done for standard clinical care purposes.</description>
    <arm_group_label>Following chemoradiation</arm_group_label>
    <arm_group_label>Concurrent to chemoradiation</arm_group_label>
    <other_name>chemoradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>40 mg of chemotherapy drug will be given weekly for 5-6 weeks.</description>
    <arm_group_label>Following chemoradiation</arm_group_label>
    <arm_group_label>Concurrent to chemoradiation</arm_group_label>
    <other_name>chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed cervical cancer.

          -  Must have adequate organ function.

        Exclusion Criteria:

          -  Subject is pregnant.

          -  Recurrent cervical cancer.

          -  Distant metastases.

          -  Malignancy within the last 5 years; basal cell carcinoma or squamous cell carcinoma of
             the skin that has undergone potentially curative therapy is permissable.

          -  Subject has had prior radiation, chemotherapy, targeted therapy, or investigational
             therapy for cervical cancer.

          -  Subject has a immunodeficiency.

          -  Known history of HIV, Hepatitis B, Hepatitis C, TB, or inflammatory bowel disease.

          -  Hypersensitivity to pembrolizumab or similar drugs.

          -  Subject has an active autoimmune disease in the past 2 years.

          -  Known history of non-infectious pneumonitis.

          -  Subject has an active infection.

          -  Subject has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases are permissible. Talk to
             Study Contact for specifics.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Duska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Camblos</last_name>
    <phone>434-243-1927</phone>
    <email>amycamblos@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Duska</last_name>
    <email>lduska@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanie Broemmelsiek</last_name>
      <phone>251-445-9866</phone>
      <email>jbroemmelsiek@health.southalabama.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tammy Mitchem-Welch</last_name>
      <phone>251-445-9649</phone>
      <email>twelch@health.southalabama.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Scalici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marquis Simms</last_name>
      <phone>410-955-8849</phone>
      <email>msimms10@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University, School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jehan Ganachaud, M.Sc.</last_name>
      <phone>314-747-9202</phone>
      <email>ganachaud.j@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Neagle, RN, BSN</last_name>
      <phone>980-442-2303</phone>
      <email>Heather.Neagle@Carolinashealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheena Clift</last_name>
      <phone>434-924-2745</phone>
      <email>SHC2WN@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Duska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INOVA Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jeffords</last_name>
      <phone>703-208-6606</phone>
      <email>Kelly.Jeffords@inova.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie R Hamilton</last_name>
      <email>mrhamilton2@vcu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Linda R Duska</investigator_full_name>
    <investigator_title>Associate Professor, Division of Gynecology Oncology</investigator_title>
  </responsible_party>
  <keyword>advanced</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

